Percent-predicted FEV1 and respiratory-related quality of life improved with 28-day triple therapy in individuals with the N1303K cystic fibrosis transmembrane conductance defect, according to data published in Lancet Respiratory Medicine.“CFTR modulators are approved for approximately 90% of people with cystic fibrosis in the [United States] and provide substantial clinical benefit,”
The American Thoracic Society is the world’s leading medical society dedicated to accelerating the advancement of global respiratory health through…
This issue brief discusses key changes to immigration policies that may take place under the second Trump administration based on his previous record and campaign…
Rationale: Uncertainty remains regarding the risks associated with single-dose use of etomidate. Objectives: To assess the use of etomidate in critically ill patients and compare…
Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace coverage by boosting existing ACA subsidies and making some people newly eligible. Enrollees…
Chronic alcohol consumption disrupts lung immunity and host defense mechanisms, rendering individuals with alcohol use disorder more susceptible to developing inflammatory lung conditions with poor…
Rationale: Uncertainty remains regarding the risks associated with single-dose use of etomidate. Objectives: To assess the use of etomidate in critically ill patients and compare…
Rationale: Sepsis care delivery—including the initiation of prompt, appropriate antimicrobials—remains suboptimal. Objectives: This study was conducted to determine direct and off-target effects of…
This webinar is sponsored by Regeneron and Sanofi Discover a breakthrough treatment in COPD! Join our lively discussion on the management of patients with a…
Few children with anaphylaxis using epinephrine auto-injectors (EAI) require additional ED treatment including epinephrine.
Audio Interview from the New England Journal of Medicine — Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under…
